CANCER:

Renal Cell Carcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Kidney Cancer (332)

Kidney Medullary Carcinoma (3)

Kidney Cancer (332)

Kidney Medullary Carcinoma (3)

›

No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pembrolizumab Sensitive: A2 - Guideline PMLive - 5 days (New A2) pembrolizumab Sensitive : A2 PMLive - 5d	pembrolizumab Sensitive: A2 - Guideline PMLive - 5 days pembrolizumab Sensitive : A2 PMLive - 5 days - (New A2)
CD3G overexpression	Renal Cell Carcinoma	CD3G overexpression	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BONSAI high signature	Renal Cell Carcinoma	BONSAI high signature	Renal Cell Carcinoma	cabozantinib tablet Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) cabozantinib tablet Sensitive : C3 ESMO 2022 - 3wk	cabozantinib tablet Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks cabozantinib tablet Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
NCAM1 overexpression	Renal Cell Carcinoma	NCAM1 overexpression	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MTOR overexpression	Renal Cell Carcinoma	MTOR overexpression	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CD4 underexpression	Renal Cell Carcinoma	CD4 underexpression	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CD27 overexpression	Clear Cell Renal Cell Carcinoma	CD27 overexpression	Clear Cell Renal Cell Carcinoma	PD1 inhibitor Resistant: C3 – Early Trials Clin Cancer Res - 3 weeks (New C3) PD1 inhibitor Resistant : C3 Clin Cancer Res - 3wk	PD1 inhibitor Resistant: C3 – Early Trials Clin Cancer Res - 3 weeks PD1 inhibitor Resistant : C3 Clin Cancer Res - 3 weeks - (New C3)
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	tivozanib Sensitive: A1 - Approval tivozanib Sensitive : A1	tivozanib Sensitive: A1 - Approval tivozanib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval bevacizumab + pegylated interferon α -2a Sensitive : A1	bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval bevacizumab + pegylated interferon α -2a Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive : A1	Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	axitinib Sensitive: A1 - Approval axitinib Sensitive : A1	axitinib Sensitive: A1 - Approval axitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	aldesleukin Sensitive: A1 - Approval aldesleukin Sensitive : A1	aldesleukin Sensitive: A1 - Approval aldesleukin Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval Krabeva (bevacizumab biosimilar) Sensitive : A1	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval Krabeva (bevacizumab biosimilar) Sensitive : A1
VHL mutation	Renal Cell Carcinoma	VHL mutation	Renal Cell Carcinoma	belzutifan Sensitive: A1 - Approval belzutifan Sensitive : A1	belzutifan Sensitive: A1 - Approval belzutifan Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	CT-P16 (bevacizumab biosimilar) Sensitive: A1 - Approval CT-P16 (bevacizumab biosimilar) Sensitive : A1	CT-P16 (bevacizumab biosimilar) Sensitive: A1 - Approval CT-P16 (bevacizumab biosimilar) Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	bevacizumab + pegylated interferon α -2a Sensitive: A2 - Guideline bevacizumab + pegylated interferon α -2a Sensitive : A2	bevacizumab + pegylated interferon α -2a Sensitive: A2 - Guideline bevacizumab + pegylated interferon α -2a Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2

Renal Cell Carcinoma

Associations(304)

Associations
(304)